

**New Mexico Bioscience Authority (BSA) Board of Directors
Regular Meeting
February 19, 2026, 11:30 AM – 1:05 PM**

Draft Meeting Minutes

Present: Paul Laur (Chair), Christos Christodoulou, Dale Dekker, Tom Kieft, Alex Koglin, Lisa Kuuttila, Francisco Pallares, David Perkins, Nora Sackett, Prisca Tiasse

Absent: Christos Christodoulou, Tanner Schaub

Staff Present: Stephanie Tofighi, Anne-Laure Schmitt Olivier, Irene Gray, Sterling Nichols, Ryan Cangioli

#	Agenda Items	Board Actions
1.	Call to order and Confirmation of Quorum	Chair Laur called the meeting to order at 11:30 AM. A quorum was confirmed.
2.	Approval of Minutes: <ul style="list-style-type: none"> January 15, 2025, BOD Meeting 	<p>Chair Laur called for a motion to approve the January 15, 2025, meeting minutes.</p> <p>A motion was made by David Perkins with a second from Francisco Pallares to approve the January 15th meeting minutes.</p> <p>A roll call vote of all board members was called with seven in the affirmative, none in opposition, one in abstention and three absent. The vote was as follows:</p> <p>Christodoulou-Absent, Dekker-Affirm, Kieft-Affirm, Koglin-Affirm, Kuuttila-Affirm, Laur-Affirm, Pallares-Affirm, Perkins-Affirm, Sackett-Absent, Schaub-Absent, Tiasse-Abstain</p>
3.	Announcements and Chair's Report	<p>NMBSA Chair Paul Laur provided his update for the month of February.</p> <p>March 2026 NMBSA Board Meeting The Chair announced that the March 19, Regular Board meeting will instead be a special session for the BOD to</p>

		<p>review and score applications submitted for the 2026 BIO International Conference Travel Grant program.</p> <p><u>Ski-Lift Pitch; February 2-3, 2026, Taos Ski Valley, New Mexico</u></p> <p>The Chair and NMBSA Director Alex Koglin attended the New Mexico Economic Development Department sponsored event that had over 100 attendees and representation from various entrepreneurs and venture capital firms. Director Koglin served as a judge for the pitch competition.</p> <p><u>Update: Former NMBSA Board Member: Dana Catron</u></p> <p>Former NMBSA Director Catron has been named the Executive Director of the Santa Fe Business Incubator in Santa Fe, New Mexico.</p> <p><u>Regional Development Corporation (RDC) Meeting; Thursday, February 19, 2026. Santa Fe, New Mexico</u></p> <p>The RDC of Northern New Mexico will conduct its regular meeting from 5:00pm-7:00pm on February 19th.</p> <p>The Chair concluded his report for the month of February.</p>
4.	Executive Director's Report	<p>NMBSA Executive Director (ED) Stephanie Tofighi provided an update on the following items for the month of February.</p> <p><u>Weigel Broadcasting</u></p> <p>ED Tofighi and NMBSA Communications and Industry Outreach Manager Irene Gray met with representatives from Weigel who conduct public broadcasts that focus on workforce development and job creation. Representatives of the Chicago based firm met with ED Tofighi and CIOM Gray to confirm a scheduled interview that will be held in March of 2026. Tofighi said the video interview will focus on the NMBSA Spring 2026 Business Entrepreneur Experience Internship Program and the BSA's current initiatives. The interview will be available via internet and</p>

		<p>television following editing and production two weeks after the interview.</p> <p><u>Meeting with IV Ensure Company of Dallas, Texas</u></p> <p>ED Tofighi and NMBSA Strategy and Policy Director Ryan Cangioli met with representatives from IV Ensure to discuss IV Ensure’s interest in connecting with peers and hospitals throughout the New Mexico for the integration of their products such as ‘take home’ IV prescriptions. Following the 2026 State of New Mexico Legislative session, Cangioli and Tofighi will meet with IV Ensure to commence introductions with Presbyterian Hospitals, University of New Mexico and the New Mexico Health Authority.</p> <p><u>Gift of Life Biologics (GLB)</u></p> <p>ED Tofighi met with the CEO from the Florida based entity to discuss possible partnership opportunities in New Mexico as GLB has expressed interest in establishing a branch operation in the western region of the United States. Tofighi pointed to partnership opportunities with UNM-HSC, UNM Cancer Center and Mesa Alta Research of Albuquerque. GLB is an industry leader in the Donor Collection of Bone Marrow and Stem Cells.</p> <p><u>Javier Davo; CEO of Canaritech; Santa Fe, NM-Mexico City</u></p> <p>Davo will present to the BOD following the <u>February 19th NMBSA President’s Report; Agenda Item 5</u></p> <p><u>Ecomap Technologies</u></p> <p>Tofighi met with Ecomap Technologies CEO Sherrod Davis to learn about the scorecard Ecomap is developing for their online platform. The scorecard assists to effectively identify the number of employees in a particular region and industry section demonstrating growth. Ecomap will also refine their methods in data collection.</p> <p>NMBSA CIOM Irene Gray is working with the Ecomap Platform team to transition the BSA’s Bioscience Ecomap to</p>
--	--	--

		<p>be directly embedded into the NMBA website which will allow users to automatically connect with the Bioscience Ecomap and bypass any registration requirements.</p> <p><u>Meeting with the New Mexico Biomedical and Biotechnology Association (NMBio)</u></p> <p>ED Tofighi and NMBSA CIOM Irene Gray met with NMBio Executive Director Janeth Pena and NMBio President Philip Lister to gather insight for integrating Central New Mexico Community College student interns into the NMBSA BEE Internship Program and future NMBSA-NMBio collaborations. Pena, invited the BSA to the upcoming NMBio Lunch & Learn Event; Thursday, February 26, 2026 11:30 PM – 12:00 PM at UNM Rainforest Innovations.</p> <p><u>Shawna Wolf – UNM Institutional Support Services</u></p> <p>Wolf and ED Tofighi discussed UNM’s plans for expansion along Albuquerque’s Lomas Boulevard corridor. They also discussed the possibility of the BSA’s proposed Incubator-Accelerator space being in the Lomas corridor.</p> <p><u>Feasibility Study Quote</u></p> <p>FBT Architecture provided a quote for the feasibility study in which ED Tofighi confirmed review of the quote which will be discussed in <i>February 19th Executive Committee Report; Agenda Item 7.</i></p> <p>ED Tofighi concluded her report.</p>
5.	President’s Report	<p>NMBSA President Dr. David Perkins presented his report for the month of February.</p> <p><u>Robert Black, New Mexico Cabinet Secretary of the New Mexico Economic Development Department</u></p> <p>President Perkins informed he will meet with Secretary Black in March of 2026 and if the BOD had any items of discussion for Secretary Black to please forward them before the March meeting.</p>

		<p><u>Artificial Intelligence in Medicine Project (AIMP)</u></p> <p>Congressionally mandated funds for the AIMP were acquired to incorporate plans for the inclusion of rural populations. With the newfound support, President Perkins said the AIMP is looking forward to continuing the AIMP project.</p> <p>President Perkins concluded his report.</p> <p>Director Nora Sackett joined the meeting at 11:46 AM.</p>
6.	Canaritech Company Presentation	<p>Francisco Javier Davó; CEO of the Santa Fe-Mexico based firm Canaritech, joined the February 19th board meeting to present on Canaritech’s strategic mission for transforming clinical research in Latin America.</p> <p>Davó is a lawyer by profession with expertise in financial and operational consulting. His extensive professional experience defines his leadership role by directing Canaritech to push for innovation in Clinical Research while improving access to advanced therapies in the region.</p> <p>Through screen share Davos presented Canaritech’s aspirations for Clinical Research.</p> <p>Canaritech</p> <p>Bridging the gap between global pharmaceutical innovation and the vast, diverse populations of Latin America.</p> <p>Canaritech began operations in 2024 under the leadership of Francisco Kuri Breña.</p> <p>Collaboration and Strategic Alliances</p> <p>Key partnerships and alliances strengthen Canaritech’s position and capabilities in the clinical research landscape:</p> <ul style="list-style-type: none"> • <i>Research Institutions</i> • <i>Healthcare Providers</i> • <i>Regulatory Bodies</i> • <i>Pharmaceutical Partners</i>

		<p>To establish the goal of transforming global clinical research, Canaritech seeks to build a bridge in the clinical trials industry with Mexico and the United States.</p> <p>Expertise & Multidisciplinary Team:</p> <p>Canaritech has a multi-disciplinary team with experience in clinical research, regulatory affairs and project management.</p> <p>Canaritech plans to hire more staff to conduct additional operations.</p> <p>Network Infrastructure</p> <p>Canaritech has built a network designed for execution throughout Latin America with representatives in</p> <ul style="list-style-type: none"> • Peru • Colombia • Brazil • Costa Rica <p>Innovation and Technology Platform</p> <p>Canaritech focuses on cost efficiency for Decentralized Clinical trials by building infrastructure to make trials more accessible. This helps in reaching a broader population across diverse geographical regions.</p> <p>Canaritech’s cost efficiency strategy is to conduct Stage 1 and Stage 2 clinical trials in Latin America and conclude with Stage 3 in the United States to pay 10% of the costs incurred.</p> <p>Acquisitions & Alliances:</p> <p>Canaritech plans to purchase a 25% share of the BIOTECMOL firm in Mexico. BIOTECMOL has expertise in advancing molecular diagnostics and vaccine development.</p>
--	--	--

		<p>Canaritech will introduce a new platform with BIOTECMOL to produce vaccines.</p> <p>Canaritech has also aligned with another Mexican company to produce animal vaccines named LAPISA. Lapisa is one of the two leading companies in Mexico engaged in vaccine development for animals.</p> <p>Capabilities: Diagnostic Solutions</p> <p><i>Diagnostic Kits & Molecular Tools</i></p> <p>Canaritech will specialize in the development and application of essential molecular biology reagents such as Molecular Diagnostic Kits for use in Mexico’s veterinarian industry.</p> <p>Research: Vaccine Development</p> <p>Canaritech has developed effective platforms to produce vaccines.</p> <p><i>Canaritech Platforms</i></p> <ul style="list-style-type: none"> • <i>VLP’s</i>: Virus Like Particles • <i>AgR</i>: Vaccines for agricultural use to boost immunity in animals • <i>Enzymes</i>. mRNA vaccine production • <i>Hormones</i>: Hormonal vaccines used to trigger responses • <i>Therapeutic Peptides</i>: short chain amino acids mimicking biological processes. <p>Product Development Pipeline</p> <p>Canaritech has two products using a baculovirus expression system:</p> <ol style="list-style-type: none"> 1. Myostatin – Muscle growth regulation. Allows muscle growth in animals such as cows or pigs at a faster rate than normal farm raising-feeding activities. Myostatin inhibitors present a 25-30 percent increase in muscular development when
--	--	--

		<p>administered. This increases cost efficiency as it accounts for a decrease in food costs to raise livestock</p> <p>2. Inhibition – A therapeutic protein candidate to increase fertility in livestock.</p> <p>Team BIOTECMEL Executive Leadership:</p> <ul style="list-style-type: none"> • Rogelio Alonso - <i>Chief Science Officer</i> • Antonio Enciso - <i>Chief Executive Officer</i> • Amanda Gayasso - <i>Chief Operations Officer</i> <p>CEO Davó concluded his presentation.</p> <p>Director Nora Sackett left the meeting at 12:00 PM.</p>
6.	<p>Executive Committee Report</p> <ul style="list-style-type: none"> • Legislative Update 	<p>NMBSA Executive Committee Chair Paul Laur presented his report for the month of February.</p> <p><u>Legislative Update</u></p> <p>New Mexico Senate Bill 177 and House Bil 2</p> <p>The Budget for the 2026 Legislative session was reported at \$11.1 Billion in which Senate Bill 177 (SB177) called for \$1.5 Billion to be transferred out of the state’s general fund into research and development in which one of the targeted industries named for R&D was Bioscience, however the Chair confirmed the emphasis was for Quantum Computing because of the national labs. New Mexico has over 150 Quantum computing scientists and one of the largest companies in quantum computing has committed in moving to New Mexico.</p> <p>The Chair continued stating that SB177 merged into New Mexico House Bill 2 (HB2) in which an additional \$40 Million was targeted for Business Recruitment and \$15 Million for Innovation hubs. NMBSA Strategy and Policy Director (SPD) Ryan Cangioli confirmed the Chair’s acknowledgment of the merging of SB177 into HB2 while adding that a complete summary of what funds were transferred into HB2 would be helpful determining what funds the BSA could apply for.</p>

	<ul style="list-style-type: none"> • Feasibility Study Update 	<p>SPD Cangiolosi went on to say that the inclusion of \$6 Million originally included in SB 177 for the Bioscience Authority was not introduced in HB2 for 2026. He went on to say that we will continue our momentum with our efforts to reinforce the need to support additional funding in 2027.</p> <p>SPD Cangiolosi then stated that New Mexico State Senator George Munoz wants to see half a billion dollars to be utilized for economic development and that the BOD should continue to look for the BSA’s eligibility to apply for available funds such as grants or additional funding vehicles originating at the EDD.</p> <p>Cangiolosi informed that the \$1 Million allocated to the BSA during 2025’ Legislative session from Representative Meredith Dixon has been re-authorized for allocation in 2026. The re-authorization will give the BSA another year to utilize these funds until Fiscal Year 2027. The BSA’s annual allocation for 2026, \$330K, is still in place.</p> <p>Before concluding the Legislative Session Update, the Chair said Senate Bill 172 (SB172) and House Bill 82 (HB82) are of particular interest. He and Director Alex Koglin attended all of the committee hearings for SB172 and HB82.</p> <p><u>Feasibility Study Update</u></p> <p>The BSA has received one bid to conduct the feasibility study. The bid was for \$107K from FBT Architects. ED Tofighi has contacted additional local architecture firms to submit bids for the study to ensure a fair amount of competition is garnered through the UNM Procurement Bidding Process involving a Request for Proposals.</p> <p>Director Dale Dekker mentioned that FBT Architecture would be an ideal candidate to submit a bid.</p> <p><u>Site Selections for the Feasibility Study</u></p> <p>ED Tofighi informed that the study will focus on two sites</p> <p><i>Site 1: Lomas Boulevard Corridor</i></p>
--	--	---

		<p>Site 2: Existing space or new space along Broadway Ave NE *(Near Fatpipe of Albuquerque Coworking Space)</p> <p>Chair Laur concluded his report.</p>
7.	<p>Finance Committee Report Monthly Financial Statement Review (January)</p> <ul style="list-style-type: none"> • BIO 2026 Travel Grant Update 	<p>NMBSA Finance Committee Chair (FCC); Alex Koglin presented the February Finance Committee Report.</p> <p>Through screen share, FCC Koglin presented the January 2026 Financial Statement.</p> <p><u>January 2026 Financial Statement</u></p> <p>FCC Koglin reported there were no significant changes to the budget for the month of January.</p> <p>FCC Koglin called for a motion to approve the January 2026 financial statement.</p> <p>A motion was made by Dale Dekker to approve the January financial statement with a second from Paul Laur.</p> <p>A roll call vote of all board members was called with eight in the affirmative, none in opposition, none in abstention and three absent. The vote was as follows:</p> <p>Christodoulou-Absent, Dekker-Affirm, Kieft-Affirm, Koglin-Affirm, Kuuttilla-Affirm, Laur-Affirm, Pallares-Affirm, Perkins-Affirm, Sackett-Absent, Schaub-Absent, Tiasse-Affirm</p> <p><u>BIO 2026 Travel Grant Update</u></p> <p>Promotion of the BIO 2026 Travel Grant application occurred on NMBSA Chair Paul Laur’s podcast. FCC Koglin said promotion was key to receiving submissions from interested companies. ED Tofighi added she would promote the Travel Grant at NMBio’s Lunch and Learn event on February 26th, 2026.</p> <p>FCC Koglin concluded his report.</p> <p>Director Lisa Kuuttilla left the meeting at 12:45 PM.</p>

8.	<p>Mission Accomplishment Committee Report</p> <ul style="list-style-type: none"> NMBSA Response to the EDD RFI 	<p>Mission Accomplishment Committee Chair Tom Kieft presented his report for the month of February.</p> <p><u>NMBSA Response to the Economic Development Department’s (EDD) Request for Information (RFI)</u></p> <p>Through screen share, MAC Chair Kieft presented the BSA’s response to the EDD’s RFI prepared by ED Tofighi and NMBSA CIOM Irene Gray. Both the MAC and Executive Committee members contributed significantly to the final version of the document. The response addressed supporting the growth of New Mexico’s Bioscience Industry by turning innovation into economic opportunity with the New Mexico Research and Development fund.</p> <p>ED Tofighi said the response was submitted February 13, 2026.</p> <p>MACC Kieft concluded his report.</p> <p>Director Prisca Tiasse left the meeting at 12:57 PM.</p>
9.	Other NMBSA Related Business Discussion	The Chair confirmed there were no NMBSA business related items to discuss for the month of February.
10.	Adjourn	<p>NMBSA Chair Laur called for a motion to adjourn the meeting.</p> <p>A motion was made by Alex Koglin to adjourn the meeting with a second from Tom Kieft.</p> <p>A roll call vote of all board members was called with six in the affirmative, none in opposition, none in abstention and five absent. The vote was as follows:</p> <p>Christodoulou-Absent, Dekker-Affirm, Kieft-Affirm, Koglin-Affirm, Kuuttila-Absent, Laur-Affirm, Pallares-Affirm, Perkins-Affirm, Sackett-Absent, Schaub-Absent, Tiasse-Absent</p> <p>The meeting adjourned at 1:05 PM.</p>

Respectfully submitted by Sterling Nichols & Stephanie Tofighi.